Emil Kakkis; President, Chief Executive Officer, Director; Ultragenyx Pharmaceutical Inc Erik Harris; Executive Vice President, Chief Commercial Officer; Ultragenyx Pharmaceutical Inc Howard Horn; ...
Zacks.com on MSN7h
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/YUltragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...
Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...
Yourgene was acquired by Novacyt in September 2023, in a £16.7m deal.
The biotechnology company, Ultragenyx, has reported a successful fourth quarter and full year 2024 financial results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback